Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. (Q48691036)
Jump to navigation
Jump to search
scientific article published in February 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. |
scientific article published in February 2016 |
Statements
1 reference
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study. (English)
1 reference
Robert Provenzano
1 reference
Anatole Besarab
1 reference
Steven Wright
1 reference
Sohan Dua
1 reference
Steven Zeig
1 reference
Peter Nguyen
1 reference
Lona Poole
1 reference
Khalil G Saikali
1 reference
Gopal Saha
1 reference
Stefan Hemmerich
1 reference
Lynda Szczech
1 reference
K H Peony Yu
1 reference
Thomas B Neff
1 reference
1 February 2016
1 reference
67
1 reference
912-924
1 reference
6
1 reference
Identifiers
1 reference
1 reference